Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
|Articles|October 4, 2007
Ranbaxy gets agency nod for generic Biaxin suspension
Clarithromycin oral suspension approved for Ranbaxy Pharmaceuticals
Advertisement
Clarithromycin for Oral Suspension, USP, has been approved by the FDA for Ranbaxy Pharmaceuticals in strengths of 125 mg/5 ml and 250 mg/5 ml. The agent is bioequivalent to Biaxin Granules in the same strengths from Abbott Laboratories. Clarithromycin is indicated for the treatment of mild to moderate infections causes by susceptible microorganisms.
To go to the Drug Topics homepage,
Advertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5